standard GHST order randomized: clonidine - arginine for Human Growth Hormone Deficiency
This trial will study whether the new macimorelin test is safe and works as well as other tests to diagnose growth hormone deficiency (GHD) in children.
- Human Growth Hormone Deficiency
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are there any other research papers which compare the results of the standard GHST order of arginine and clonidine?
"The randomized standard order of GHST: arginine - clonidine was first trialled in 2021 at Azienda Ospedaliero-Universitaria Anna Meyer. So far, there have been 59 completed studies with 1 currently active trial. Many of these studies are conducted in Greenwood Village, Colorado."
Is the combination of arginine and clonidine in GHST form safe for patients?
"Standard GHST order randomized: arginine - clonidine has received a safety score of 3 from our team at Power. This is because it is a Phase 3 trial, which means that there is both efficacy and safety data from multiple rounds of testing."
Does age limit eligibility for participation in this trial?
"Children that are above the age of 2 and under the age of 17 are eligible for this clinical trial."